Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and Perrigo Company plc

A Decade of Innovation: R&D Spending Trends in Biopharma

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Perrigo Company plc have demonstrated contrasting trajectories in their R&D investments.

From 2014 to 2023, TG Therapeutics, Inc. has shown a remarkable increase in R&D expenses, peaking in 2021 with a 533% rise from its 2014 levels. This surge underscores the company's aggressive pursuit of new therapies and treatments. In contrast, Perrigo Company plc's R&D spending has been more stable, with a slight decline of 20% from its 2018 peak.

These trends reflect broader industry dynamics, where smaller biotech firms like TG Therapeutics are rapidly scaling their R&D efforts, while established players like Perrigo maintain steady investment levels. As the biopharma sector continues to innovate, these spending patterns offer valuable insights into each company's strategic priorities.